Log In
Print
BCIQ
Print
Print this Print this
 

imilecleucel-T (Tcelna) (formerly Tovaxin)

Also known as: T-cell vaccine

  Manage Alerts
Collapse Summary General Information
Company Opexa Therapeutics Inc.
DescriptionPatient-specific myelin reactive T cells (MRTCs) primed and expanded ex vivo with myelin-associated peptides
Molecular Target T cell receptor (TCR)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS); Treat secondary progressive multiple sclerosis (SPMS)
Regulatory Designation U.S. - Fast Track (Treat secondary progressive multiple sclerosis (SPMS))
Partner Merck KGaA

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$228.0M

0

$195.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today